Labcorp Holdings (LH) announced the commercial release of its H5 bird flu molecular test to support the diagnosis of human H5 bird flu infections.
The test, developed with the support of the Centers for Disease Control and Prevention, is available in the US for physicians to order for suspected H5N1 infections in people, the company said Tuesday in a statement.
Health-care providers can order the test for suspected cases using nasopharyngeal swab specimens to analyze polymerase chain reactions, the company said.
The US faces a multistate poultry and dairy cow outbreak of H5 bird flu with recent cases found in industry workers.
Labcorp shares rose 1% in recent Tuesday trading.
Price: 231.81, Change: +2.19, Percent Change: +0.95